DS7300-188
Everyone
info
50+
Downloads
Everyone
Learn more
About this app
A Phase 3, Multicenter, Randomized, Open Label Study Of Ifinatamab Deruxtecan (I Dxd), A B7-H3 Antibody Drug Conjugate (Adc), Versus Treatment Of Physician’s Choice (Tpc) In Subjects With Relapsed Small Cell Lung Cancer (Sclc). This app is specifically intended for participants in the ds7300-188 study only.
You are invited to participate in the Daiichi Sankyo - DS7300-188 study.
Updated on
Safety starts with understanding how developers collect and share your data. Data privacy and security practices may vary based on your use, region, and age. The developer provided this information and may update it over time.
- No data shared with third partiesLearn more about how developers declare sharing
- No data collectedLearn more about how developers declare collection
- Data is encrypted in transit
What’s new
Bug fixes
Everyone
Learn moreApp support
About the developer
Medable Inc.
tim@medable.com
525 University Ave Ste A70
Palo Alto, CA 94301
United States
+1 650-231-5478
